Sharma P, Jhawat V, Mathur P, Dutt R. Innovation in cancer therapeutics and regulatory perspectives. Med Oncol. 2022;39(5):76.

PubMed  PubMed Central  Google Scholar 

Maharati A, Moghbeli M. Role of microRNAs in regulation of doxorubicin and paclitaxel responses in lung tumor cells. Cell Div. 2023;18(1):11.

CAS  PubMed  PubMed Central  Google Scholar 

Kibria G, Hatakeyama H, Harashima H. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system. Arch Pharm Res. 2014;37(1):4–15.

CAS  PubMed  Google Scholar 

Zangouei AS, Alimardani M, Moghbeli M. Micrornas as the critical regulators of doxorubicin resistance in breast tumor cells. Cancer Cell Int. 2021;21(1):213.

CAS  PubMed  PubMed Central  Google Scholar 

Khan SU, Fatima K, Aisha S, Malik F. Unveiling the mechanisms and challenges of cancer drug resistance. Cell Commun Signal. 2024;22(1): 109.

PubMed  PubMed Central  Google Scholar 

Moghbeli M, Mosannen Mozaffari H, Memar B, Forghanifard MM, Gholamin M, Abbaszadegan MR. Role of MAML1 in targeted therapy against the esophageal cancer stem cells. J Transl Med. 2019;17(1):126.

PubMed  PubMed Central  Google Scholar 

Khan SU, Fatima K, Malik F. Understanding the cell survival mechanism of anoikis-resistant cancer cells during different steps of metastasis. Clin Exp Metas. 2022;39(5):715–26.

Google Scholar 

Khan SU, Fatima K, Malik F, Kalkavan H, Wani A. Cancer metastasis: molecular mechanisms and clinical perspectives. Pharmacol Ther. 2023;250: 108522.

CAS  PubMed  Google Scholar 

Karas BF, Hotz JM, Buckley BT, Cooper KR. Cisplatin alkylating activity in zebrafish causes resistance to chorionic degradation and inhibition of osteogenesis. Aquat Toxicol. 2020;229: 105656.

CAS  PubMed  PubMed Central  Google Scholar 

Zangouei AS, Moghbeli M. Micrornas as the critical regulators of cisplatin resistance in gastric tumor cells. Gen Environ : Off Japanese Environ Mutagen Soc. 2021;43(1):21.

CAS  Google Scholar 

Moghbeli M. Micrornas as the critical regulators of Cisplatin resistance in ovarian cancer cells. J Ovarian Res. 2021;14(1): 127.

CAS  PubMed  PubMed Central  Google Scholar 

Navaei ZN, Khalili-Tanha G, Zangouei AS, Abbaszadegan MR, Moghbeli M. PI3K/AKT signaling pathway as a critical regulator of Cisplatin response in tumor cells. Oncol Res. 2021;29(4):235–50.

PubMed  Google Scholar 

Maharati A, Moghbeli M. Forkhead box proteins as the critical regulators of cisplatin response in tumor cells. Eur J Pharmacol. 2023;956: 175937.

CAS  PubMed  Google Scholar 

Xu J, Gewirtz DA. Is autophagy always a barrier to Cisplatin therapy? Biomolecules. 2022. https://doi.org/10.3390/biom12030463.

PubMed  PubMed Central  Google Scholar 

Moghbeli M. Micrornas as the pivotal regulators of cisplatin resistance in osteosarcoma. Pathol - Res Pract. 2023;249: 154743.

CAS  PubMed  Google Scholar 

Zandberga E, Kozirovskis V, Abols A, Andrejeva D, Purkalne G, Line A. Cell-free microRNAs as diagnostic, prognostic, and predictive biomarkers for lung cancer. Genes Chromosomes Cancer. 2013;52(4):356–69.

CAS  PubMed  Google Scholar 

Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–83.

CAS  PubMed  Google Scholar 

Tolue Ghasaban F, Maharati A, Akhlaghipour I, Moghbeli M. Micrornas as the critical regulators of autophagy-mediated cisplatin response in tumor cells. Cancer Cell Int. 2023;23(1):80.

CAS  PubMed  PubMed Central  Google Scholar 

Maharati A, Moghbeli M. Forkhead box proteins as the critical regulators of cisplatin response in tumor cells. Eur J Pharmacol. 2023;956: 175937.

CAS  PubMed  Google Scholar 

Carter K, Rameshwar P, Ratajczak MZ, Kakar SS. Verrucarin j inhibits ovarian cancer and targets cancer stem cells. Oncotarget. 2017;8(54):92743–56.

PubMed  PubMed Central  Google Scholar 

Nakano T, Warner KA, Oklejas AE, Zhang Z, Rodriguez-Ramirez C, Shuman AG, et al. mTOR inhibition ablates cisplatin-resistant salivary gland cancer stem cells. J Dent Res. 2021;100(4):377–86.

CAS  PubMed  Google Scholar 

Nor C, Zhang Z, Warner KA, Bernardi L, Visioli F, Helman JI, et al. Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer. Neoplasia. 2014;16(2):137–46.

PubMed  PubMed Central  Google Scholar 

Schaefer T, Lengerke C. SOX2 protein biochemistry in stemness, reprogramming, and cancer: the PI3K/AKT/SOX2 axis and beyond. Oncogene. 2020;39(2):278–92.

CAS  PubMed  Google Scholar 

Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev. 2003;17(1):126–40.

CAS  PubMed  PubMed Central  Google Scholar 

Weina K, Utikal J. SOX2 and cancer: current research and its implications in the clinic. Clin Transl Med. 2014;3(1):1–10.

Google Scholar 

Cui F, Hao Zx, Li J, Zhang Yl, Li Xk, He Jx. SOX2 mediates cisplatin resistance in small-cell lung cancer with downregulated expression of hsa-miR-340-5p. Mol Genet Genomic Med. 2020;8(5): e1195.

CAS  PubMed  PubMed Central  Google Scholar 

Cui F, Hao ZX, Li J, Zhang YL, Li XK, He JX. SOX2 mediates cisplatin resistance in small-cell lung cancer with downregulated expression of hsa-miR-340-5p. Mol Genet Genomic Med. 2020;8(5): e1195.

CAS  PubMed  PubMed Central  Google Scholar 

He J, Shi J, Zhang K, Xue J, Li J, Yang J, et al. Sox2 inhibits Wnt-beta-catenin signaling and metastatic potency of cisplatin-resistant lung adenocarcinoma cells. Mol Med Rep. 2017;15(4):1693–701.

CAS  PubMed  PubMed Central  Google Scholar 

Mamun MA, Mannoor K, Cao J, Qadri F, Song X. SOX2 in cancer stemness: tumor malignancy and therapeutic potentials. J Mol Cell Biol. 2020;12(2):85–98.

PubMed  Google Scholar 

Mirzaei S, Paskeh MDA, Entezari M, Mirmazloomi SR, Hassanpoor A, Aboutalebi M, et al. SOX2 function in cancers: association with growth, invasion, stemness and therapy response. Biomed Pharmacother. 2022;156: 113860.

CAS  PubMed  Google Scholar 

Hutz K, Mejias-Luque R, Farsakova K, Ogris M, Krebs S, Anton M, et al. The stem cell factor SOX2 regulates the tumorigenic potential in human gastric cancer cells. Carcinogenesis. 2014;35(4):942–50.

PubMed  Google Scholar 

Tian T, Zhang Y, Wang S, Zhou J, Xu S. Sox2 enhances the tumorigenicity and chemoresistance of cancer stem-like cells derived from gastric cancer. J Biomed Res. 2012;26(5):336–45.

CAS  PubMed  PubMed Central  Google Scholar 

Maharati A, Moghbeli M. PI3K/AKT signaling pathway as a critical regulator of epithelial-mesenchymal transition in colorectal tumor cells. Cell Commun Signal. 2023;21(1): 201.

CAS  PubMed  PubMed Central  Google Scholar 

Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discovery. 2005;4(4):307–20.

CAS  PubMed  Google Scholar 

Kornakiewicz A, Solarek W, ZBielecka F, LianSzczylikCzarnecka FCMA. Mammalian target of rapamycin inhibitors resistance mechanisms in clear cell renal cell carcinoma. Curr Signal Transduct Ther. 2013;8(3):210–8.

CAS  PubMed Central  Google Scholar 

Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–93.

CAS  PubMed  PubMed Central  Google Scholar 

Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci. 2007;104(41):16158–63.

CAS  PubMed  PubMed Central  Google Scholar 

Xie L-X, Sun F-F, He B-F, Zhan X-F, Song J, Chen S-S, et al. Rapamycin inhibited the function of lung CSCs via SOX2. Tumor Biol. 2016;37:4929–37.